View a Transcript of the Podcast here

From Protein Science R&D to Therapeutics: Expert Insights (Part 1)

Thomas Laue, Ph.D., Professor, Biochemistry and Molecular Biology; Director, Biomolecular Interaction Technologies Center (BITC), University of New Hampshire
Bjørn Voldborg, MSc, Director, CHO Cell Line Development, The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark
Andrew Fosberry, Ph.D., Senior Scientific Investigator, Protein and Cellular Sciences, GlaxoSmithKline
Dr. Thomas Laue of University of New Hampshire, Bjørn Voldborg of Technical University of Denmark, and Dr. Andrew Fosberry of GlaxoSmithKline speak to Cambridge Healthtech Institute. They are part of “It’s a Wrap”, the closing plenary panel discussion representing various R&D stages at PepTalk: The Protein Science Week, January 9-13 in San Diego, California.

View a Transcript of the Podcast here

Every Protein Is Different: Difficult Targets, GPCRs and Drug Discovery

Ian Hunt, Ph.D., Head, Protein Sciences, Center for Proteomic Chemistry, Novartis Institutes for BioMedical Research
Dr. Ian Hunt of Novartis speaks to CHI on December 1, 2015. Dr. Hunt will be presenting during the Applying Expression Platforms conference at 2016’s PepTalk, January 18-22 in San Diego, California.
Topics include development of high-throughput protein technologies and different strategies to make more difficult proteins, the recent explosion in technologies to solve X-ray crystallography of GPCRs, applying such technologies into the drug discovery context, generation of very large protein complexes and more.